Vaxfab Enterprises Ltd (542803)
சுருக்கம்
The board meets on 14 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 14 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 15 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 11 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 14 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Vaxfab Enterprises Ltd-இன் இயக்குநர் குழுக் கூட்டம் 14 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Vaxfab Enterprises' revenue was ₹0.4 Cr, and net profit ₹-3.1 Cr; the operating margin was -1412.1%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.4 | — | -97.4% |
| செயல்பாட்டு லாபம் | ₹-5.6 | — | நஷ்டமாக |
| நிகர லாபம் | ₹-3.1 | — | நஷ்டம் குறைந்தது |
| EPS (₹) | -1.20 | — | நஷ்டம் குறைந்தது |
| செயல்பாட்டு லாப வரம்பு | -1412.1% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Vaxfab Enterprises Limited has notified BSE that its Board of Directors will meet on Saturday, November 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The company's trading window closed on October 01, 2026, and will remain shut until 48 hours following the results announcement. The company reported TTM net losses of Rs -12 Cr and a sharp revenue drop to Rs 0.4 Cr in the June 2026 quarter.
- Board meeting scheduled on Saturday, November 14, 2026
- To approve unaudited financial results for quarter and half year ended September 30, 2026
- Trading window closure in effect since October 01, 2026, extending to 48 hours post-results
- Filing submitted on November 11, 2026
Vaxfab Enterprises has appointed M/s. ASGM & Co., Chartered Accountants, to conduct an independent forensic audit and investigation covering FY23, FY24, and FY25. The investigation was initiated following the management transition on April 01, 2025, where primary accounting, purchase, and statutory records were reportedly missing. In addition, the company has received notices from GST authorities regarding historical transactions and input tax credit claims. The professional fee approved for the audit is ₹3,00,000 plus taxes.
- Forensic audit covers 3 full financial years: FY 2022-23, FY 2023-24, and FY 2024-25
- Initiated after historical records were not handed over during the management transition on April 01, 2025
- Audit scope includes investigating GST notices and input tax credit claims alongside Tally integrity and bank reconciliations
- Board approved auditor professional fees of ₹3,00,000 plus applicable taxes (with an initial retainer of ₹1,50,000)
Vaxfab Enterprises has approved raising funds up to Rs 45.00 crore through a rights issue of equity shares of face value Rs 10 each. The proposed fundraise represents approximately 94% of the company's net worth (Rs 48 crore) and 4.5% of its market capitalization (Rs 995 crore). The board also approved the Draft Letter of Offer to be filed with BSE Limited and constituted a Rights Issue Committee. Issue price, rights entitlement ratio, and record date will be determined subsequently.
- Rights issue approved for an aggregate amount of up to Rs 45,00,00,000 (Rs 45 crore)
- Proposed securities are equity shares with a face value of Rs 10.00 each
- Draft Letter of Offer approved for filing with BSE Limited
- Rights Issue Committee formed comprising 3 members under Chairman Ravindra Ashokbhai Joshi
Vaxfab Enterprises Ltd has scheduled a Board of Directors meeting on October 01, 2026, to consider augmenting financial resources via fundraising. The proposed methods include preferential allotment, rights issue, QIP, ADR/GDR, FCCBs, or other securities in one or more tranches. The quantum and structure of the capital raise remain unspecified. The company's trading window is closed from September 25, 2026, until 48 hours post-board meeting.
- Board meeting scheduled for Thursday, October 01, 2026
- Fundraise proposed via equity, convertible instruments, rights issue, QIP, or FCCBs
- Trading window closed effective September 25, 2026 until 48 hours after the meeting
Vaxfab Enterprises has approved the allotment of 8,26,761 equity shares of face value Rs 10 each upon conversion of warrants on a preferential basis to 9 investors. The shares were allotted at an issue price of Rs 21.02 each, bringing in the remaining conversion consideration of Rs 15.765 per warrant (aggregating to ~Rs 1.30 crore). Following this allotment, the company's paid-up equity capital increased to Rs 25.83 crore across 2,58,26,406 equity shares. The newly allotted shares rank pari-passu with existing equity shares.
- Allotted 8,26,761 equity shares of Rs 10 face value upon warrant conversion to 9 investors
- Conversion price received was Rs 15.765 per warrant against total issue price of Rs 21.02 per share
- Paid-up equity share capital expanded to Rs 25,82,64,060 comprising 2,58,26,406 equity shares
- Results in ~3.2% dilution of the post-allotment equity base
Vaxfab Enterprises reported a sharp decline in financial performance for the quarter ended June 30, 2026. Standalone revenue from operations slumped to ₹0.40 Cr (₹40.00 Lakhs) compared to ₹14.57 Cr in Q1 FY26. Standalone net loss stood at ₹5.84 Cr versus a net profit of ₹0.39 Cr in the year-ago period, heavily impacted by notional losses on fair valuation of investments. On a consolidated basis, revenue stood at ₹0.40 Cr with a net loss attributable to owners of ₹3.04 Cr.
- Standalone revenue from operations fell sharply to ₹0.40 Cr (₹40.00 Lakhs) from ₹14.57 Cr in Q1 FY26
- Standalone net loss widened to ₹5.84 Cr (₹584.09 Lakhs) compared to a net profit of ₹0.39 Cr in Q1 FY26
- Consolidated net loss attributable to owners stood at ₹3.04 Cr (₹303.65 Lakhs)
- Management attributed the loss primarily to a notional loss on fair valuation of investments under Ind AS 109
- Paid-up equity share capital increased to ₹25.26 Cr (₹2525.96 Lakhs) from ₹8.40 Cr
Vaxfab Enterprises has incorporated a wholly-owned subsidiary (WOS) in the UAE named Al Rafa Enterprise FZ-LLC on August 6, 2026. The subsidiary is based in the Ras Al Khaimah Economic Zone and will engage in diverse activities including seeds trading, packaging materials, and IT consultancy. The initial capital is being paid in cash at AED 1,000 per share, though the total investment amount was not disclosed. This move marks an international expansion for the company, which reported a FY26 revenue of Rs 94.11 Cr and a net profit of Rs 3.64 Cr.
- 100% ownership established in the new UAE-based entity Al Rafa Enterprise FZ-LLC
- Incorporation completed on August 6, 2026, under the Ras Al Khaimah Economic Zone Authority
- Initial share price for the subsidiary set at AED 1,000.00 per share
- Business mandate covers 5+ sectors including Seeds Trading, IT Consulting, and General Trading
- Company reported TTM revenue of Rs 94 Cr and Net Worth of Rs 48 Cr prior to this expansion
Vaxfab Enterprises Ltd has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company reported a TTM revenue of Rs 94 Cr, but quarterly performance has shown significant volatility, with revenue dropping from Rs 55.04 Cr in September 2025 to Rs 8.83 Cr in March 2026. The trading window for designated persons has been closed since July 01, 2026, in anticipation of these results.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours after result submission
- TTM revenue stands at Rs 94 Cr with a thin TTM PAT of Rs 1 Cr
- Previous quarter (Mar 2026) revenue was Rs 8.83 Cr, a sharp decline from Rs 55.04 Cr in Sep 2025
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
